Home » Authors » Cormac Sheridan

Cormac Sheridan

Articles

ARTICLES

Aptuit Paying $64M For Evotec Chemistry Unit

Sep. 12, 2007

By Cormac Sheridan

Aptuit Paying $64M For Evotec Chemistry Unit

Sep. 12, 2007

By Cormac Sheridan

MediGene Gets $21M In Private Share Placement

Sep. 12, 2007

By Cormac Sheridan

FDA OKs TopoTarget's Totect For Extravasation Treatment

Sep. 12, 2007

By Cormac Sheridan

Aptuit Paying $64M For Evotec Chemistry Unit

Sep. 12, 2007

By Cormac Sheridan

Aptuit Paying $64M For Evotec Chemistry Unit

Sep. 12, 2007

By Cormac Sheridan

FDA OKs TopoTarget's Totect For Extravasation Treatment

Sep. 12, 2007

By Cormac Sheridan

MediGene Gets $21M In Private Share Placement

Sep. 12, 2007

By Cormac Sheridan

Forest Terminates Interest In Paion's Desmoteplase

Sep. 5, 2007

By Cormac Sheridan

Jerini Goes Solo With Icatibant In U.S. As Abbott Walks Out

Sep. 5, 2007

By Cormac Sheridan

View All Articles by Cormac Sheridan

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 26, 2026.
Brain-computer interfaces are here but long road ahead
BioWorld
The field of BCI is continually evolving; as such, companies are increasingly highlighting the potential of their technologies to transform care. For advanced...
Next wave of BCI firms builds on pioneers to tackle challenges
BioWorld
With the pace of neurotechnology development accelerating, a wave of brain-computer interface (BCI) companies is emerging on the heels of the pioneers. In the...
ENCALS 2026: From genetics to advancing strategies against ALS
BioWorld Science
Amyotrophic lateral sclerosis (ALS)-associated genes provide direct therapeutic targets and reveal pathways that can be used to develop treatments that counteract...
Boehringer Ingelheim identifies new mGlu3 receptor agonists
BioWorld Science
Boehringer Ingelheim Pharma GmbH & Co. KG and Vanderbilt University have discovered new dihydrobenzoxazine compounds acting as metabotropic glutamate mGlu3...